Aborted Secondary Share Offering and the Underlying Reasons for Funding Failure

Summit Therapeutics (SMMT) abruptly withdrew its planned $500 million secondary share offering just one day after its announcement, citing deteriorating market conditions. This decision reflects concerns surrounding the global clinical data of ivonescimab (development code SMT112/AK112), a bispecific antibody cancer drug candidate co-developed with its Chinese partner, Akeso (9926.HK). Despite the overall favorable fundraising environment, with the biotech index rising more than 30% compared to a year ago, the company failed to secure funding due to the market's high sensitivity to individual clinical data. This serves as a prime example of how timing is crucial in fundraising.

Controversy and Efficacy Concerns Regarding Global Clinical Data

ivonescimab demonstrated promising results in the HARMONi-2 (Phase 3) trial in China, showing a significant improvement in progression-free survival (PFS) compared to Merck's (MSD) standard of care, Keytruda (pembrolizumab) (Hazard Ratio 0.51, p < 0.0001). However, concerns about global efficacy arose when interim analysis data from the ongoing global Phase 3 trial (HARMONi-3) revealed that the progression-free survival in the squamous NSCLC cohort did not reach the pre-specified statistical significance threshold. This has amplified the long-standing concerns within the medical and investor communities regarding whether the positive data observed in China can be replicated in a global, multi-regional setting involving patients of diverse ethnicities. This ultimately led to a sharp decline in the company's stock price and the withdrawal of the share offering.

Financial Runway and the Sustainability of Pipeline Development

As of March 31, 2026, Summit Therapeutics holds approximately $600 million in cash and short-term investments, so it is not facing an immediate liquidity crisis. However, the company's financial burden has increased due to the licensing agreement with Akeso in December 2022, under which Akeso acquired rights to ivonescimab in the United States, Canada, Europe, and Japan for a total of $5 billion (including an upfront payment of $500 million and potential milestone payments and royalties). The company is conducting a large-scale, multi-regional HARMONi-3 global Phase 3 trial for non-small cell lung cancer and a HARMONi-7 trial targeting patients with high expression levels, which costs hundreds of millions of dollars annually. Major investment banks, such as Leerink Partners, have warned that Summit's financial runway may expire around 2027, before commercialization milestones are reached. Therefore, the failure of this fundraising effort is likely to exacerbate financial risks and potentially delay clinical schedules and increase future funding costs.

Competitive Landscape and Regulatory Hurdles in the Non-Small Cell Lung Cancer Market

The global non-small cell lung cancer (NSCLC) treatment market is a key area with an estimated size of $24 billion in 2026, growing at a compound annual growth rate of approximately 12%. Currently, Keytruda, which generated revenues of $29.48 billion in 2024 and $31.7 billion in 2025, dominates the market as the standard of care, and other bispecific antibody pipelines, such as BNT327 from BioNTech, are rapidly catching up. Ivonescimab received its first approval from the National Medical Products Administration (NMPA) in China on May 24, 2024, as an EGFR-mutated non-squamous NSCLC treatment (brand name: Aiduyi, 依沃西). However, to achieve global standard of care status and secure FDA approval, it is crucial to demonstrate the final overall survival (OS) data from HARMONi-3 and validate the results in a multi-regional clinical setting.